T. Rowe Price Associates’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

T. Rowe Price Associates’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,492	Closed	-$6K	–	2989
2023 Q1	$6K	Hold	13,492	–	–	﹤0.01%	2897
2022 Q4	$16K	Buy	13,492 +2,516	+23%	+$4.1K	﹤0.01%	2885
2022 Q3	$26K	Buy	+10,976	New	+$28.7K	﹤0.01%	2904

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CGC

Continental Grain Company New York $448M AUM 6.81% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return

T. Rowe Price Associates's GRNA Position: Q2 2023 in Review

T. Rowe Price Associates sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2023, closing a stake of 13,492 shares — an estimated $6K sold.

T. Rowe Price Associates first reported a position in GRNA in Q3 2022 and held it in 3 quarters. The position peaked at $26K in Q3 2022. 48 funds tracked by Wall St. Rank hold GRNA as of Q2 2023.

T. Rowe Price Associates reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 13,492 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2023, an estimated $6K.
T. Rowe Price Associates first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2022 and held it in 3 quarters.
T. Rowe Price Associates's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $26K in Q3 2022.
48 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.